HER2-targeted therapies are also adopted in other cancers (such as non-small cell lung cancer [NSCLC] and colorectal cancer) when HER2-positive was identified, although they are still not approved for those patients due to inadequate evidence (1). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.